IJBPAS, March, 2025, 14(3): 1834-1856

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

PRECISION MEDICINE AND REGULATORY PERSPECTIVE: A COMPARATIVE ANALYSIS OF USFDA AND EMA REGULATIONS

YUSUF M[1], KARTHIKEYAN VETRIVEL[1], VIVEKANANDAN ELANGO[2], KSHITIJA DILIP NIKAM[1] AND MURUGAPPAN M[1*]

[1]Department of Pharmaceutical Regulator Affairs, JSS College of Pharmacy, Ooty, Nilgiris, Tamil Nadu, India

yusufm8055@gmail.com (Y.M) (Orcid Id: 0009-0003-8264-2495)

karthikeyan18072001@gmail.com (K.K.V) (Orcid Id: 0009-0009-7443-8252);

[1*]Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Nilgiris, Tamil Nadu, India

murugappan92@jssuni.edu.in (M.M) (Orcid Id: 0000-0003-3062-6568)

[2]Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Nilgiris, Tamil Nadu, India

vivekanandanej@gmail.com (V.E) (Orcid Id: 0009-0009-0908-5294);

kshitijanikam1999@gmail.com (K.D.N) (Orcid Id: 0009-0009-7131-6727).

***Corresponding Author: Dr. Murugappan M: E Mail: murugappan92@jssuni.edu.in**

Received 9th Sept. 2024; Revised 18th Oct. 2024; Accepted 29th Nov. 2024; Available online 1st March 2025

https://doi.org/10.31032/IJBPAS/2025/14.3.9720

ABSTRACT

A revolutionary approach to medical care customizing healthcare to match patient-specific traits reliant on genetic variables, environmental extremes and lifestyle patterns is what precision medicine is all about. In this article, we explore the opinions of regulators concerning this area of specialization. More specifically, it looks at how the US Food and Drug Administration (USFDA) and the European Medicines Agency (EMA) have responded to Precision Medicine issues. Main aspects of precision medicine include genetic medicine, pharmacogenomics, biomarker-driven therapies and sophisticated diagnostics. The relevance of precision medicine is put across in terms of its impacts on treatment effectiveness, reducing adverse effects and contribution to medical knowledge. Some of the key regulatory challenges are: ensuring that genomic tests are analytically and clinically valid; addressing issues regarding data privacy; and developing suitable reimbursement models. The reviewed article addresses the regulatory frameworks of US Food and Drug Administration (USFDA) and European Medicines Agency (EMA) in depth, delving into such initiatives as USFDA's Precision Medicine

Initiative and EMA's Adaptation Pathways approach. The evolving regulatory landscape is captured in case studies of approved precision medicine products. Forecasts future trends in precision medicine regulation, such as incorporation of real-world evidence, regulation of artificial intelligence and machine learning, and addressing ethical issues in advanced therapies. In conclusion, the author argues that regulatory frameworks must continue to be refined at a pace with ever-growing technological innovations so as to ensure safety of patients y*et al*so afford them equal access to the precise drug development.

Keywords: Precision medicine, Genomics, Regulatory challenges, USFDA, EMA

INTRODUCTION

Over the past 10 years, precision medicine, a highly innovative approach to healthcare that takes into account individual diversity in genes, environment, and lifestyle, has demonstrated itself to be a transformative force in medical practice and research **[1]**. Applying medical treatments that are specifically designed to match individual patient characteristics instead generic prescriptions like before is going to bring in change and improve identification, management, treatment of diseases in future. This change is rooted in the growing fields of genomics, bioinformatics and data analytics **[2]**.

Although it was not brand new, precision medicine became a huge deal after 2003's Human Genome Project **[3]**. To create a more accurate grouping of human diseases, clinical information should be merged with molecular data. The vision of putting together molecular data and clinical information in coming up with a finer group of human diseases was outlined in the 2011 landmark report "Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and A New Taxonomy of Disease" by National Research Council **[4]**.

In essence, precision medicine is a dynamic approach having various components such as genomic medicine, pharmacogenomics, biomarker-based therapy and personalized treatments that rely on molecular profiling **[5]**. These strategies have the potential of increasing the effectiveness of care, reducing side effects and cutting down on the cost of treatment by preventing overuse of resources **[6]**. Take for example precision oncology - which has brought about treatments specifically directed at certain types of cancer cells, giving better results on the one hand but lessening other related issues caused by old fashioned cancer treatment methods on the other **[7]**.

Nevertheless, the actualization of the potential of precision medicine is envisaged as an enormous challenge for the current regulatory frameworks that have always been centered on population-based

approaches to medicine **[8]**. The US Food and Drug Administration (USFDA) and the European Medicines Agency (EMA) are some of the global regulatory bodies striving to modify their procedures to keep up with the intricate concepts of precision medicine as they uphold their basic mandate of safeguarding the safety, efficiency and quality of medicines **[9, 10]**.

The Precision Medicine Initiative from the US Food and Drug Administration (USFDA) has been working on new strategies for regulating next-generation genome sequencing technologies, and incorporating real-world data into regulatory decisions **[11]**. In the same way, European Medicines Agency (EMA) has developed guidelines to be used to develop drugs (pharmacogenomic) with regards to the use of genetic information **[12]**. There are common challenges that both health and drug regulatory agencies face. These include validation of biomarkers, co-development of drugs and diagnostic tests and assessment of intricate algorithms applied in precision medicine applications **[13]**.

PRECISION MEDICINE

Precision medicine is a field that is both expanding and developing in health care, and it focuses on patient-specific data and biological indicators, such as clinical, hereditary, genomic, and environmental information **[14]**. Precision medicine at its core aims to group individuals into subpopulations which differ in susceptibility of getting a particular disease, the biology or prognosis of the diseases they may develop or their response to specific treatment **[2]**. This stratification makes it possible to perform more accurate and efficient interventions and in turn may raise outcomes quality by lowering negative consequences and getting rid of inappropriate treatments.

Key components of precision medicine include

Genomic Medicine

It involves the use of an individual's genomic details for steering medical decisions that may involve the analysis of gene variations linked to susceptibility to illnesses, reactions to drugs and others such as health **[3]**.

Pharmacogenomics

This domain is dealing with drugs and how they work accordingly to specific plans of individuals. Its goal is to make choices and measure of drugs be in agreement with genetic data of a certain person which will help in diminishing side effects and eventually increasing treatment efficiency **[15]**.

Biomarker-Driven Therapies

Biological markers also referred to as biomarkers are certain measures or tests that serve as an early indicator for any disease present within our body or analyze an individual's overall health. In precision medicine, biomarkers provide guidance on

who will most likely benefit from particular treatments **[16]**.

Targeted Therapies

These medications or different materials halt the growth and spread of illness by interrupting distinctive molecular objectives. For instance, in oncology, targeted treatments act against precise tumour cells with a potential outcome that could be better than it is now by minimizing toxicities relative to classical chemotherapy **[7]**.

Advanced Diagnostics

This consists of the techs like next-generation sequencing, liquid biopsies and molecular imaging that supply full data concerning the molecular status of a person's disease **[17]**.

Data Integration and Analytics

Precision medicine is heavily dependent on the amalgamation and examination of vast biological, clinical, and environmental data. Advanced computational methods, with artificial intelligence and machine learning as examples of these, have entered the arena to decode these puzzles, which results in some nuggets of wisdom **[18]**.

One of the main areas where precision medicine has registered remarkable achievements is oncology, with the diagnosis of particular gene mutations in various types of cancers resulting in the production of focused treatment methods that have greatly bettered the lives of patients **[19]**. Likewise, in the case of rare diseases, genomic may be used to thoroughly identify such patients that were earlier, hard to identify **[20]**.

Nevertheless, the full realization of precision medicine potential has various challenges including biological system complexity, large scale data integration requirement, ethical concerns on genetic information and readjusting health care systems as well as regulatory structures to fit them **[21]**.

Precision medicine is a growing area with unique challenges for the various regulatory frameworks that govern it in different countries. Traditional regulatory paradigms are better suited to interventions targeting entire populations than to handling the intricacies of personalized treatment and diagnosis **[8]**. This requires a thoughtful investigation of extant regulatory viewpoints and formulation of fresh ways towards ensuring safe and effective execution of precision medicine.

WHY PRECISION MEDICINE IS IMPORTANT?

Precision medicine is multifaceted and involves several dimensions of patient care and scientific study in contemporary healthcare.

Enhanced Treatment Efficacy

It is possible to create treatments which are more precise and efficient through the use of precision medicine. Thus, medical

practitioners can identify drugs best suited for particular people based on their genetic code along with other personal aspects. According to a Schwaederle *et al*. (2015) study, oncologists are achieving better results through such personalized approaches (as shown by better response rates) as compared to standard therapies (rate of 30.6% versus 4.9% in each case) **[7]**.

Minimized Adverse Effects

Tailoring treatments to individual patients may help reduce the frequency and severity of adverse drug reactions. This means that precision medicine considers genetic differences that may significantly alter how drugs are broken down in a person's body. In some studies, for example, pharmacogenomic testing is said to have decreased negative drug responses by 30% **[15]**.

Cost-Effectiveness

Despite being costly, introducing precision medicine approach can also result in saving money in the future. For instance, research conducted by Verbelen *et al*. (2017) revealed that having pharmacogenomic tests in medical institutions could ultimately save $5 billion every year hence worth implementing in different parts of the USA **[22]**.

Early Disease Detection and Prevention

In the case of identifying people who have a genetic composition that predisposes them to various ailments, high chances of getting sick are more likely to be linked with those whose genetic profiles are known because they can be targeted for early interventions as well as precautionary treatments. One such powerful tool involves testing whether or not one carries certain breast cancer genes namely BRCA1 and BRCA2, which has greatly changed what used to be done in order to lower incidences among women at higher menace **[23]**.

Advancement of Medical Knowledge

Precision medicine generates data that adds a high level of comprehension of sicknesses and their basic mechanisms thus illuminating us further concerning such ailments. Since its launching in 2018, the National Institutes of Health (NIH's) "All of Us" Research Program looks forward to gathering genetic and health information from one million varied individuals so as to hasten research in this area in a better way **[24]**.

Patient Empowerment

Patient involvement in healthcare decisions is promoted in precision medicine. This is done by providing patients with tailored information on their medical risks and treatment alternatives, which make them better placed in deciding what care they want to receive. Research conducted by Yanes *et al* (2020), discovered that preventive behaviours are more likely done by individuals who got personalized genetic risk information **[25]**.

Improved Drug Development

In drug development processes today, the usage of precision medicine principles is on the rise. With this technique, a specific group of patients who would gain the most from the medication is selected, leading to expedited clinical trials. In his 2015 comprehensive analysis, Schork noted that precision medicine methodologies might minimize the quantity and length of trials hence speeding up approval of drugs **[26]**.

Addressing Health Disparities

Personalized medicine has the possibility of solving health disparities by taking into account genetic differences among various races. Nevertheless, this promise can simply become true when studies include different kinds of individuals. This is what undertakings like National Institutes of Health (NIH's) All of Us program is doing; through welcoming individuals residing in regions that are not represented enough **[27]**.

Integration with Digital Health Technologies

When the precise discipline of medicine converges with digital health technologies like wearable items and mobile health apps, it presents new openings that allow constant health monitoring and unique medical treatments. Such an interaction is capable of supplying immediate data for treatment choices and lifestyle advice **[18]**.

REGULATORY CHALLENGES FOR PRECISION MEDICINE

Precision medicine has great potential to boost patient outcomes. However, it poses peculiar regulatory challenges. These challenges arise from the complex nature of genomic technologies, the fast rate at which new scientific breakthroughs occur, as well as the necessity for balancing innovation against patient safety. Below are key regulatory challenges within precision medicine domain:

Analytical and Clinical Validity of Genomic Tests

Achieving significant challenge analytical clinical validity genome tests posed. Standards that need to be put in place include determining suitable measurement for test's accuracy, reliability, and validity. The intricacy of genetic data together with its likelihood for unintentional disclosures is what makes it even harder **[28, 29]**.

Data Privacy and Security

The use of massive genomic & health data in precision medicine yields grave confidentiality issues. Authorities must create structures that safeguard patients' data y*et al*low it for research and clinical applications. Global repercussions await data management in precision medicine due to the rollout of legislations such as the General Data Protection Regulation (GDPR) in Europe **[30, 31]**.

Informed Consent

We have difficulty gaining fully informed consent in precision medicine in as much.

This is because genetic information is complex and there are possibilities for incidental findings. Shaping regulatory perspective on informed consent is necessary to enable compliance in with patient's right to decide their treatment guided by need, on one hand, and with advantages of wide data access, on the other hand **[32]**.

Reimbursement and Health Economics

Creating suitable reimbursement models for precision medicine approaches is a huge hurdle. Evaluators and payers need to know how much precision medicine interventions are worth and fit them in the health systems that already exist **[33]**.

Regulation of AI and Machine Learning in Healthcare

As AI and machine learning becomes more common with precision medicine, it presents new regulatory issues. Safety and efficacy evaluation frameworks need to be developed by regulators for medical devices and algorithms that are based on AI **[34]**.

Harmonizing International Regulations

The globalization typical of all biomedical research and care services requires that global standards be put in place. The discrepancy among regulatory approaches across nations might act as a barrier towards related innovations **[35]**.

Controlling of Direct-to-Consumer Genetic Testing

In view of the growing market for direct-to-consumer genetic tests, key regulatory challenges include ensuring that tests are valid, that consumers are educated appropriately, and that genetic information is protected against misuse **[36]**.

The Ethical Use of Gene Editing Technologies

In light of CRISPR-Cas9, there are many moral and regulatory issues that accompany gene editing. Therefore, in order to ensure that research is done in an ethical way and uses these inventions responsibly, there needs to be guidelines set up which will govern different regulatory organizations **[37]**.

Equitable Access to Precision Medicine

A central regulatory challenge is to guarantee inclusivity in the application of precision medicine. This should guide the way the regulators approach the issue of worsening of health disparities due to uneven distribution of sophisticated medical technologies **[38]**.

Regulation of Multi-Omics Approaches

A number of 'omics' technologies in precision medicine (e.g., genomics, proteomics, metabolomics) have made it hard to integrate, interpret and regulate data **[39]**.

Pharmacogenomic Drug Labeling

The challenge of drafting suitable guidelines for incorporating pharmacogenomic data in drug labeling is constantly in front of

stakeholders. Those in control need to strike a balance between current genetic information and how drugs are practically manufactured and distributed **[10]**.

Regulation of Digital Health Technologies

The introduction of digital and health innovation in precision medicine poses significant challenges to the achievement of data accuracy, interoperability and patient safety **[40]**.

Designs of Clinical Trials Based on Adjustment

New regulatory approaches are needed to develop frameworks for evaluating adaptive and novel trial designs in precision medicine development. Regulators must ensure that such designs are rigorously evaluated from a scientific point of view **[41]**.

USFDA REGULATORY PERSPECTIVES ON PRECISION MEDICINE

The US Food and Drug Administration (USFDA) has been leading in the development of regulatory frameworks that support the progress of precision medicine and keep patients safe and ensure treatment efficacy. Several key initiatives and guidelines constitute the US Food and Drug Administration (USFDA's) precision medicine regulation approach:

Precision Medicine Initiative (PMI)

The Precision Medicine Initiative (PMI) which was started in 2015, aims to boost biomedical research and deliver clinicians, new tools and therapies to deal with precision medicine **[1]**. The US Food and Drug Administration (USFDA) plays a crucial role in this initiative by:

- Making regulations for Next Generation Sequencing (NGS) technologies.
- Curating databases to prove genes validity for use in hospitals.
- Making the approval of companion diagnostics easier.

Next Generation Sequencing (NGS) Tests

Next Generation Sequencing (NGS) tests are crucial for precision medicine applications; hence US Food and Drug Administration (USFDA) has developed a flexible approach to regulating them. In 2017, the FDA released two guidance documents on this issue:

- Application of human public genetic variant databases to validate clinical validity of genetic and genomic based in vitro diagnostics **[42]**.
- Design, Development, and Analytical Validation Considerations of Next Generation Sequencing–Based In Vitro Diagnostics Intended for Assisting with the Diagnosis of Suspected Germline Diseases **[43]**.

The purpose of these rules is to simplify the process of regulating the NGS tests by

upholding the high standards of analytical and clinical validity.

Companion Diagnostics

The US Food and Drug Administration (USFDA) has established a set of procedures aimed at ensuring the development and validation of assays to be used in medicines meant for individual patients. The 2014 Guidance document "In vitro companion diagnostic devices" outlines the regulatory approach by the agency in the control of those tests **[44]**.

Real-World Evidence (RWE) Program

With real-world data and regulatory decisions in mind, the US Food and Drug Administration (USFDA) started the Real-World Evidence (RWE) Program in 2018 **[45]**. To assess the feasibility of using real-world evidence in deciding the safety and efficacy of products, a perspective highly pertinent in precision medicine methods.

Biomarker Qualification Program

The US Food and Drug Administration (USFDA's) Biomarker Qualification Program has devised a scheme for the emergence and ratification of regulatory biomarkers significant in precision medicine **[46]**. The program helps in the utilization of endorsed biomarkers in the procedures related to drug approval and development.

Pharmacogenomics

Incorporation of pharmacogenomic information in drug labeling is something the US Food and Drug Administration (USFDA) has done. To date, over 500 US Food and Drug Administration (USFDA) approved drugs have pharmacogenomic information in their labeling as at the start of 2021. The federal agency has guidelines for drug labeling about pharmacogenomic information format and content **[47, 48]**.

Accelerated Approval Pathways

The US Food and Drug Administration (USFDA) has some paths for accelerating approvals which are suitable for precision therapies:

- Fast Track Designation
- Breakthrough Therapy Designation
- Priority Review
- Accelerated Approval

These pathways may speed up the process of creating and testing new drugs to address severe illnesses, particularly those showing marked clinical benefits compared to other currently used treatment approaches **[49]**.

Innovative Designs for Clinical Trials

The US Food and Drug Administration (USFDA) has shown openness to such kind of innovative clinical trial design that is especially suited for precision medicine approaches. These include:

- Umbrella trials
- Adaptive trial designs
- Basket trials

In 2019, the agency published directions concerning the use of adaptive designs in

clinical trials for supporting drug development **[50]**.

Digital Health Technologies

The convergence of precision medicine and digital health is hereby being recognized; specifically, the US Food and Drug Administration (USFDA) has come up with some frameworks for regulating digital health technologies. The Digital Health Innovation Action Plan basically outlines what they intend to do together with protecting public health as stipulated in it by the agency **[51]**.

Artificial Intelligence and Machine Learning

The US Food and Drug Administration (USFDA) has been creating regulatory frameworks for these systems, as AI and Machine Learning become more critical in applications involving the precise medical care. Regulatory framework proposal for SaMDs based on AI/ML describes how this organization has viewed rapid technological development in this direction **[52]**.

EMA REGULATORY PERSPECTIVES ON PRECISION MEDICINE

The European Medicines Agency (EMA) has dedicated much effort to produce standards that foster the improvement of precision medicine and, at the same time, provide security for patients' lives and effectiveness of treatment. The European Medicines Agency (EMA) has some significant steps and advice on precision medicine regulation:

Adaptation Pathways

The idea of adaptive pathways by European Medicines Agency (EMA) supports a quicker and step-by-step patient reach to new drugs, especially in the case of personalized medicines is what the European Medicines Agency (EMA) introduced **[53]**. This approach involves:

- Iterative development
- Gathering evidence through real-world use to supplement clinical trial data
- Early involvement of patients and health technology assessment bodies

Biomarker Qualification

With a precision medicine in mind, European Medicines Agency (EMA) has put in place a process for biomarker qualification **[54]**. This process includes:

- Scientific advice on biomarker development
- Qualification opinion on the acceptability of a specific use of the proposed biomarker
- Letters of support encouraging further data generation on promising biomarkers

Pharmacogenomics Working Party

This group offers advice for every area in pharmacogenetics tied into sensing the value of drugs **[55]**. Key activities include:

- Developing guidelines on the use of pharmacogenomic methodologies in pharmacovigilance
- Providing advice on the pharmacogenomic aspects of drug development
- Contributing to the development of product information relating to pharmacogenomics

Companion Diagnostics

The European Medicines Agency (EMA) has close working relationships with notified bodies, which are responsible for conformity assessments of in vitro diagnostic medical devices as well as companion diagnostics **[56]**. The agency:

- Provides scientific input on the suitability of a companion diagnostic
- Consults with notified bodies during the marketing authorization process for related medicinal products

Advanced Therapy Medicinal Products (ATMPs)

The European Medicines Agency (EMA's) particular guidelines for advanced therapy medicinal products encompass gene therapies, somatic cell therapies, and tissue-engineered products **[57]**. These guidelines address:

- Quality, non-clinical, and clinical aspects of ATMPs
- Risk-based approach to ATMPs development
- Long-term follow-up of patients receiving ATMPs

Real-World Evidence (RWE)

The European Medicines Agency (EMA) has been looking into the use of real-world evidence that can be used in the regulation decision-making processes, this is particularly important in precision medicine **[58]**. Initiatives include:

- The Big Data Steering Group, focusing on the use of big data in medicine evaluation
- Guidance on the use of registry-based studies to support regulatory decision-making

Data Protection and Ethical Considerations

The European Medicines Agency (EMA) functions under the General Data Protection Regulation (GDPR) that has major consequences in terms of precision medicine research and applications **[59]**. The agency:

- Provides guidance on data protection in the context of clinical trials and pharmacovigilance
- Collaborates with ethics committees to address ethical issues in precision medicine

Innovative Designs for Clinical Trials

The European Medicines Agency (EMA) has shown openness to such kind of innovative clinical trial design that is

especially suited for precision medicine approaches **[60]**. These include:

- Basket trials
- Umbrella trials
- Adaptive designs

Orphan Medicinal Products

A plethora of precise healthcare treatments is aimed toward infrequent ailments. The European Medicines Agency (EMA) is known for its strategies in order to promote the creation of exceptional medicine **[61]**, including:

- Protocol assistance
- Market exclusivity
- Fee reductions for regulatory procedures

Paediatric Investigation Plans

In accordance with the European Medicines Agency (EMA), all new drugs have to have their Paediatric Investigation Plans; precision medicine strategies should also be developed for children when needed **[62]**.

International Collaboration

To harmonize regulatory approaches to precision medicine, including, the European Medicines Agency (EMA) takes part in international collaborations:

- The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) **[63]**
- The International Medical Device Regulators Forum (IMDRF) **[64]**

Artificial Intelligence and Machine Learning

In the area of precision medicine, AI and ML are increasingly vital in the development of medical devices and drugs, and so the European Medicines Agency (EMA) is creating guidelines for how they ought to be regulated **[65]**.

CASE STUDIES OF PRECISION MEDICINE PRODUCTS APPROVED BY THE USFDA AND EMA

Several advanced therapies have been formulated and approved due to Precision Medicine. The transformation in personalized healthcare is indicated through selected examples of precision medical products sanctioned by US Food and Drug Administration (USFDA) and European Medicines Agency (EMA), which are presented in these case studies.

Imatinib was approved in 2001 by the US Food and Drug Administration (USFDA) and European Medicines Agency (EMA), the same year

When it comes to personalizing medicine in its initial stages Gleevec marked a milestone. In the context of CML patients possessing the Philadelphia Chromosome, this drug functions as an inhibitor competing with BCR-ABL oncoprotein **[66]**.

Key Points

- Dramatically improved survival rates for CML patients
- Demonstrated the potential of targeted therapies in oncology
- Led to a paradigm shift in cancer treatment approaches

US Food and Drug Administration (USFDA) has approved Trastuzumab in 1998 and in 2000 European Medicines Agency (EMA) also approved

As a monoclonal antibody directed against HER2-positive breast cancer, trastuzumab was one of the first instances of tying a treatment to its corresponding diagnostic test **[67]**.

Key Points

- For patients with breast cancer HER2-positive outcomes improved critically
- Emphasizing the significance of biomarker testing in selecting treatment
- Paved the way for other targeted therapies in breast cancer

The US Food and Drug Administration (USFDA) approved Zelboraf (Vemurafenib) in 2011 with European Medicines Agency (EMA) approving it a year later in 2012

Vemurafenib was developed to target metastatic melanoma patients with the BRAF V600E mutation. Upon approval, a companion diagnostic test was created for screening these candidates **[68]**.

Key Points

- Demonstrated quick approval based on a huge clinical benefit
- Highlighted the importance of companion diagnostics in precision medicine
- Showed the Promise of Targeted Therapies in Treating Melanoma

US Food and Drug Administration (USFDA) Approves Olaparib (Lynparza) in 2014 and European Medicines Agency (EMA) approved in 2014

The PARP inhibitor olaparib was first licensed to treat ovarian cancer with a BRCA mutation. Since then, additional BRCA-mutated malignancies have been added to its list of approved uses **[69]**.

Key Points

- First PARP inhibitor approved for cancer treatment
- Demonstrated the potential of synthetic lethality in cancer therapy
- Approval expanded based on basket trial results

US Food and Drug Administration (USFDA) approved pembrolizumab under a tissue-agnostic indication in 2017, European Medicines Agency (EMA) followed suit in 2019

Pembrolizumab received approval as the pioneer cancer medication on the basis of an indicator of this condition rather than just the organ it is in. This approval is for unresectable or metastatic solid tumors that are microsatellite instability-high (MSI-H)

or mismatch repair deficient (dMMR) among both adults as well as children **[70]**.

Key Points

- First ever approval in oncology irrespective of tissue displayed
- Showcased immunotherapy's promise in customized healthcare
- Basic in cancer management is genetic testing as it has shown

Larotrectinib (Vitrakvi) Approved by US Food and Drug Administration (USFDA): 2018 Approved by European Medicines Agency (EMA): 2019

Larotrectinib targets NTRK gene fusions across different types of solid tumors. It was one of the first "tumor-agnostic" therapies approved based on a common biomarker rather than the location of the tumor **[71]**.

Key Points

- This approval came from assessing three clinical trials together
- In multiple kinds of cancers, rare gene changes were found as targets
- Highlighted the importance of comprehensive genomic profiling in cancer diagnosis

Lumacaftor/Ivacaftor (Orkambi) Approved by US Food and Drug Administration (USFDA): 2015 Approved by European Medicines Agency (EMA): 2015

This combination therapy targets specific mutations in the CFTR gene responsible for cystic fibrosis. It represents a significant advance in the treatment of this genetic disease **[72]**.

Key Points

- The potential of precision medicine in genetic disorders has been demonstrated
- It is important to highlight that understanding the molecular basis of a disease is fundamental
- Showed the value of combination therapies in addressing complex genetic conditions

The US Food and Drug Administration (USFDA) approved Nusinersen (also known as Spinraza) and in 2016 the substance found itself outside the borders of the US as it was approved by the European Medicines Agency (EMA)

Unlike any other drugs used for treatment, Nusinersen is an antisense oligonucleotide specifically designed for treating the SMA which results from mutations of the SMN1 gene **[73]**.

Key Points

- SMA's premier endorsed remedy
- It has shown promise for RNA-targeting therapeutic agents
- Highlight the urgency of prompt genetic testing along with medical management.

The US Food and Drug Administration (USFDA) granted its approval for Luxturna (voretigene neparvovec) in

2017, followed by European Medicines Agency (EMA) in 2018

Patients suffering from retinal dystrophy caused by a biallelic RPE65 mutation that has been proven effective. This is also named gene therapy with voretigene neparvovec **[74]**.

Key Points

- First directly administered gene therapy approved in the USA
- Demonstrated the potential of gene therapy in treating inherited disorders
- Highlighted the importance of genetic testing in rare diseases

Onasemnogene abeparvovec (Zolgensma) Approved by US Food and Drug Administration (USFDA): 2019 Approved by European Medicines Agency (EMA): 2020

Onasemnogene abeparvovec is a gene therapy for spinal muscular atrophy (SMA) caused by mutations in the SMN1 gene **[75]**.

Key Points

- One-time gene therapy for a severe genetic disorder
- Demonstrated the potential of AAV vector-based gene therapies
- Highlighted regulatory challenges in pricing and reimbursement for high-cost, one-time therapies

FUTURE OUTLOOK FOR PRECISION MEDICINE REGULATIONS

With quick evolution of precision medicine, regulatory frameworks need to change along with scientific advancements but in a way that ensures patient safety as well as ethics. Future perspectives toward precision medicine regulations are expected to have a significant emphasis on several core aspects:

Adaptive Licensing and Real-World Evidence (RWE)

Regulatory Agencies are likely to develop adaptive licensing approaches even more and use real world evidence (RWE) to make regulatory decisions better **[76]**.

- Integration of real-world evidence (RWE) in post-marketing surveillance
- Development of standards for real world evidence (RWE) quality and analysis
- Refinement of adaptive pathways for precision medical products

Regulation of Artificial Intelligence and Machine Learning

As AI and ML are increasingly situated in the nucleus of precision medicine; regulators must adapt this evolution by putting in place more holistic frameworks for this technology **[34]**.

- Validation of AI/ML algorithms in healthcare
- Regulation of continuous learning AI systems
- Ethical considerations in AI-driven medical decision-making

Next-Generation Sequencing (NGS) and Multi-Omics Approaches

The complexity of Next-Generation Sequencing (NGS) and multi-omics data in diagnostics and treatment selection has to be addressed by regulators using Next-Generation Sequencing (NGS) and Multi-Omics Approaches **[77]**.

- Standardization of Next-Generation Sequencing (NGS) test validation
- Guidelines for interpretation and reporting of complex genomic data
- Regulation of integrated multi-omics approaches

Gene Editing and Advanced Therapies

Advancing gene editing technologies like CRISPR-Cas9 and cell therapies at such a pace will necessitate the evolution of regulatory frameworks **[78]**.

- Safety and efficacy standards for gene editing therapies
- Long-term follow-up requirements for advanced therapies
- Ethical guidelines for germline gene editing

Data privacy and security

As large-scale data sharing is crucial for precision medicine; laws will also have to juggle data usefulness and privacy protection **[30, 31]**.

- Development of secure data sharing platforms
- Implementation of dynamic consent models
- Regulations for cross-border data transfers

Patient-centered methods and health equity

It is likely that regulators will focus more on equitable access to precision medicine and patient participation **[79]**.

- Integration of patient-reported outcomes in regulatory decision-making
- Guidelines for inclusive clinical trial designs
- Policies to promote equitable access to precision medicine

Pharmacogenomics and Drug Labeling

Ongoing regulatory adaptations are required for integrating pharmacogenomic information into drug development and clinical practice **[15]**.

- Standardization of pharmacogenomic testing and reporting
- Guidelines for updating drug labels with new genomic information
- Regulation of direct-to-consumer pharmacogenomic testing

Regulatory Science and Capacity Building

There is still a need for regulatory agencies to build their scientific capabilities so that

they can evaluate complex precision medicines **[80]**.

- Training programs for regulators in genomics and bioinformatics
- Collaboration with academic institutions and industry
- Development of computational tools for regulatory review

CONCLUSION

The review we have conducted at the regulatory approaches of both the US Food and Drug Administration (USFDA) and the European Medicines Agency (EMA) towards precision medicine pointed out the following. Indeed, it is true that they admit the ability of precision medicine to improve the results of a patient though notable differences can be observed in their regulations. The US Food and Drug Administration (USFDA's) adoption of a more proactive stance and implementation of a variety of guidance documents for companion diagnostics in addition to genome sequencing tests contrasts with the European Medicines Agency (EMA's) strategy, which is more evolutionary and based on repurposing existing frameworks to address precision medicine technologies. The two organizations face the same difficulties such as the need to standardize the validation process of biomarkers; ensure data privacy and other issues stemming from the complexity of combination products. The distinction between the two lies in the manner they deal with them where the US Food and Drug Administration (USFDA) provides more detailed rules as compared to European Medicines Agency (EMA) based on principles. In the future, closer cooperation among these regulators would enable global precision medicine product development. In addition, both agencies have to further refine their frameworks to match fast-paced technological changes in the industry. We require further studies to analyze the innovation horizon, access to markets, and patient outcomes of precision medicine that has had long-term effects due to certain regulations.

REFERENCES

[1] F. S. Collins and H. Varmus, "A New Initiative on Precision Medicine," *New England Journal of Medicine*, vol. 372, no. 9, pp. 793–795, Feb. 2015, doi: 10.1056/nejmp1500523.

[2] J. L. Jameson and D. L. Longo, "S o u n d i n g B o a r d Precision Medicine-Personalized, Problematic, and Promising," 2015.

[3] E. D. Green, J. D. Watson, and F. S. Collins, "Twenty-five years of big biology," 2015.

[4] *Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease*. Washington, 2011.

[5] G. S. Ginsburg and K. A. Phillips, "Precision medicine: From science to

value," *Health Aff*, vol. 37, no. 5, pp. 694–701, 2018, doi: 10.1377/hlthaff.2017.1624.

[6] V. J. Dzau and G. S. Ginsburg, "Realizing the full potential of precision medicine in health and health care," Oct. 25, 2016, *American Medical Association*. doi: 10.1001/jama.2016.14117.

[7] M. Schwaederle *et al.*, "Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials," *Journal of Clinical Oncology*, vol. 33, no. 32, pp. 3817–3825, Nov. 2015, doi: 10.1200/JCO.2015.61.5997.

[8] M. A. Hamburg and F. S. Collins, "The Path to Personalized Medicine," *New England Journal of Medicine*, vol. 363, no. 4, pp. 301–304, Jul. 2010, doi: 10.1056/nejmp1006304.

[9] J. Woodcock and L. M. LaVange, "Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both," *New England Journal of Medicine*, vol. 377, no. 1, pp. 62–70, Jul. 2017, doi: 10.1056/nejmra1510062.

[10] F. Ehmann *et al.*, "Pharmacogenomic information in drug labels: European Medicines Agency perspective," Jun. 26, 2015, *Nature Publishing Group*. doi: 10.1038/tpj.2014.86.

[11] "U.S. Food and Drug Administration. (2018). Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development."

[12] European Medicines Agency, "Guideline on good pharmacogenomic practice."

[13] J. Love-Koh *et al.*, "The Future of Precision Medicine: Potential Impacts for Health Technology Assessment," *Pharmacoeconomics*, vol. 36, no. 12, pp. 1439–1451, Dec. 2018, doi: 10.1007/s40273-018-0686-6.

[14] P. Khamkat, V. Barik, B. Bhusan Barik, S. Mohapatra, and R. Kar, "PERSONALIZED MEDICINE: AN INNOVATION IN HEALTH-CARE SYSTEM," vol. 15, p. 2022, 2022, doi: 10.22159/ajpcr.2022v15i10.45460.

[15] M. V. Relling and W. E. Evans, "Pharmacogenomics in the clinic," Oct. 14, 2015, *Nature Publishing Group*. doi: 10.1038/nature15817.

[16] R. V. NAIR and K. S, "REVOLUTIONIZING DRUG DISCOVERY: UTILIZING BIOMARKERS FOR PRECISION MEDICINE AND TARGETED THERAPIES," *Asian Journal of Pharmaceutical and Clinical Research*, pp. 8–15, Jul. 2024, doi: 10.22159/ajpcr.2024v17i7.51039.

[17] M. Cronin and J. S. Ross, "Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology," Jun. 2011. doi: 10.2217/bmm.11.37.

[18] E. J. Topol, "High-performance medicine: the convergence of human and artificial intelligence," Jan. 01, 2019, *Nature Publishing Group*. doi: 10.1038/s41591-018-0300-7.

[19] F. Meric-Bernstam *et al.*, "Feasibility of large-scale genomic testing to facilitate

enrollment onto genomically matched clinical trials," *Journal of Clinical Oncology*, vol. 33, no. 25, pp. 2753–2762, Sep. 2015, doi: 10.1200/JCO.2014.60.4165.

[20] K. M. Boycott *et al.*, "International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases," May 04, 2017, *Cell Press*. doi: 10.1016/j.ajhg.2017.04.003.

[21] M. J. Khoury, M. Gwinn, M. S. Bowen, and W. D. Dotson, "Beyond Base Pairs to Bedside: A Population Perspective on How Genomics Can Improve Health," *Am J Public Health*, vol. 102, pp. 34–37, 2012, doi: 10.2105/AJPH.2011.

[22] M. Verbelen, M. E. Weale, and C. M. Lewis, "Cost-effectiveness of pharmacogenetic-guided treatment: Are we there yet?," Oct. 01, 2017, *Nature Publishing Group*. doi: 10.1038/tpj.2017.21.

[23] K. B. Kuchenbaecker *et al.*, "Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers," *JAMA*, vol. 317, no. 23, pp. 2402–2416, Jun. 2017, doi: 10.1001/jama.2017.7112.

[24] "The 'All of Us' Research Program", doi: 10.1056/NEJMsr1809937.

[25] T. Yanes, A. M. Willis, B. Meiser, K. M. Tucker, and M. Best, "Psychosocial and behavioral outcomes of genomic testing in cancer: a systematic review," *European Journal of Human Genetics*, vol. 27, no. 1, pp. 28–35, Jan. 2019, doi: 10.1038/s41431-018-0257-5.

[26] "A WORLD OF DIFFERENCE," 2015. [Online]. Available: www.tannerproject.org

[27] L. A. Hindorff *et al.*, "Prioritizing diversity in human genomics research," Mar. 01, 2018, *Nature Publishing Group*. doi: 10.1038/nrg.2017.89.

[28] M. J. Khoury *et al.*, "A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health," *PLoS Med*, vol. 15, no. 8, Aug. 2018, doi: 10.1371/journal.pmed.1002631.

[29] R. C. Green *et al.*, "ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing," *Genetics in Medicine*, vol. 15, no. 7, pp. 565–574, 2013, doi: 10.1038/gim.2013.73.

[30] E. W. Clayton, C. M. Halverson, N. A. Sathe, and B. A. Malin, "A systematic literature review of individuals' perspectives on privacy and genetic information in the United States," Oct. 01, 2018, *Public Library of Science*. doi: 10.1371/journal.pone.0204417.

[31] M. Shabani and P. Borry, "Rules for processing genetic data for research purposes in view of the new EU General Data Protection Regulation /706/689/179 /706/689 review-article," Feb. 01, 2018, *Nature Publishing Group*. doi: 10.1038/s41431-017-0045-7.

[32] P. S. Appelbaum *et al.*, "Models of consent to return of incidental findings in genomic research," *Hastings Center*

Report, vol. 44, no. 4, pp. 22–32, 2014, doi: 10.1002/hast.328.

[33] K. A. Phillips *et al.*, "Payer coverage policies for multigene tests," Jul. 12, 2017, *Nature Publishing Group*. doi: 10.1038/nbt.3912.

[34] J. He, S. L. Baxter, J. Xu, J. Xu, X. Zhou, and K. Zhang, "The practical implementation of artificial intelligence technologies in medicine," Jan. 01, 2019, *Nature Publishing Group*. doi: 10.1038/s41591-018-0307-0.

[35] D. Chalmers *et al.*, "Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era Donna Dickenson, Sandra Soo-Jin Lee, and Michael Morrison," Jul. 12, 2016, *BioMed Central Ltd.* doi: 10.1186/s12910-016-0124-2.

[36] M. A. Allyse, D. H. Robinson, M. J. Ferber, and R. R. Sharp, "Direct-to-Consumer Testing 2.0: Emerging Models of Direct-to-Consumer Genetic Testing," Jan. 01, 2018, *Elsevier Ltd*. doi: 10.1016/j.mayocp.2017.11.001.

[37] *Human genome editing: Science, ethics, and governance*. National Academies Press, 2017. doi: 10.17226/24623.

[38] D. E. Pritchard, F. Moeckel, M. S. Villa, L. T. Housman, C. A. McCarty, and H. L. McLeod, "Strategies for integrating personalized medicine into healthcare practice," Mar. 01, 2017, *Future Medicine Ltd.* doi: 10.2217/pme-2016-0064.

[39] K. J. Karczewski and M. P. Snyder, "Integrative omics for health and disease," May 01, 2018, *Nature Publishing Group*. doi: 10.1038/nrg.2018.4.

[40] A. Coravos, S. Khozin, and K. D. Mandl, "Developing and adopting safe and effective digital biomarkers to improve patient outcomes," Dec. 01, 2019, *Nature Publishing Group*. doi: 10.1038/s41746-019-0090-4.

[41] P. Pallmann *et al.*, "Adaptive designs in clinical trials: Why use them, and how to run and report them," Feb. 28, 2018, *BioMed Central Ltd.* doi: 10.1186/s12916-018-1017-7.

[42] C. Cber, "Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics - Guidance for Stakeholders and Food and Drug Administration Staff." [Online]. Available: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidan

[43] "Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS)-Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases Guidance for Stakeholders and Food and Drug Administration Staff." [Online]. Available: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInform

[44] "In Vitro Companion Diagnostic Devices Guidance for Industry and Food and Drug Administration Staff Preface Public Comment," 2014. [Online]. Available: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/de

[45] "Framework for FDA's Real-World Evidence Program," 2018. [Online]. Available: www.fda.gov

[46] S. Amur, L. Lavange, I. Zineh, S. Buckman-Garner, and J. Woodcock, "Biomarker qualification: Toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization," *Clin Pharmacol Ther*, vol. 98, no. 1, pp. 34–46, Jul. 2015, doi: 10.1002/cpt.136.

[47] Fda and Cder, "Table of Pharmacogenomic Biomarkers in Drug Labeling NDA/ANDA/BLA Number, Label Version Date Drug Therapeutic Area* Biomarker † Labeling Sections Labeling Text ‡."

[48] Zhang, Amur, and Huang, "Guidance for Industry Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling," 2008. [Online]. Available: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

[49] J. J. Darrow, J. Avorn, and A. S. Kesselheim, "FDA Approval and Regulation of Pharmaceuticals, 1983-2018," *JAMA - Journal of the American Medical Association*, vol. 323, no. 2, pp. 164–176, Jan. 2020, doi: 10.1001/jama.2019.20288.

[50] Fda, Cder, Bent, and Robyn, "Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry," 2019. [Online]. Available: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htmand/or

[51] "Digital Health Innovation Action Plan."

[52] "Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)-Discussion Paper and Request for Feedback." [Online]. Available: https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm514737.pdf.

[53] European Medicines Agency, "Final report on the adaptive pathways."

[54] "Qualification of novel methodologies for drug development: guidance to applicants." [Online]. Available: www.ema.europa.eu/contact

[55] European Medicines Agency, "Pharmacogenomics Working Party."

[56] Ema, "Guideline on the quality requirements for drug-device combinations."

[57] European Medicines Agency, "Advanced therapy medicinal products: Overview."

[58] A. Cave, X. Kurz, and P. Arlett, "Real-World Data for Regulatory Decision Making: Challenges and Possible

Solutions for Europe," Jul. 01, 2019, *Nature Publishing Group*. doi: 10.1002/cpt.1426.

[59] J. M. M. Rumbold and B. Pierscionek, "The effect of the general data protection regulation on medical research," *J Med Internet Res*, vol. 19, no. 2, Feb. 2017, doi: 10.2196/jmir.7108.

[60] N. Stallard *et al.*, "Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19," *Stat Biopharm Res*, vol. 12, no. 4, pp. 483–497, Oct. 2020, doi: 10.1080/19466315.2020.1790415.

[61] L. Fregonese *et al.*, "Demonstrating significant benefit of orphan medicines: analysis of 15 years of experience in Europe," Jan. 01, 2018, *Elsevier Ltd*. doi: 10.1016/j.drudis.2017.09.010.

[62] European Medicines Agency, "10-year Report to the European Commission: General report on the experience acquired as a result of the application of the Paediatric Regulation."

[63] ICH, "International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)."

[64] IMDRF, "International Medical Device Regulators Forum (IMDRF)."

[65] T. Minssen, S. Gerke, M. Aboy, N. Price, and G. Cohen, "Regulatory responses to medical machine learning," *J Law Biosci*, vol. 7, no. 1, Jan. 2020, doi: 10.1093/jlb/lsaa002.

[66] B. J. Druker *et al.*, "Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia A BS T R AC T." [Online]. Available: www.nejm.org

[67] D. J. Ennis S Lamon *et al.*, "The New England Journal of Medicine USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2 Background The HER2 gene, which encodes the," 2001. [Online]. Available: www.nejm.org

[68] P. B. Chapman *et al.*, "Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation," *New England Journal of Medicine*, vol. 364, no. 26, pp. 2507–2516, Jun. 2011, doi: 10.1056/nejmoa1103782.

[69] J. Ledermann *et al.*, "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial," *Lancet Oncol*, vol. 15, no. 8, pp. 852–861, 2014, doi: 10.1016/S1470-2045(14)70228-1.

[70] L. Marcus, S. J. Lemery, P. Keegan, and R. Pazdur, "FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors," *Clinical Cancer Research*, vol. 25, no. 13, pp. 3753–3758, 2019, doi: 10.1158/1078-0432.CCR-18-4070.

[71] A. Drilon *et al.*, " Efficacy of Larotrectinib in TRK Fusion–Positive

Cancers in Adults and Children ," *New England Journal of Medicine*, vol. 378, no. 8, pp. 731–739, Feb. 2018, doi: 10.1056/nejmoa1714448.

[72] C. E. Wainwright *et al.*, " Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR ," *New England Journal of Medicine*, vol. 373, no. 3, pp. 220–231, Jul. 2015, doi: 10.1056/nejmoa1409547.

[73] R. S. Finkel *et al.*, "Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy," *New England Journal of Medicine*, vol. 377, no. 18, pp. 1723–1732, Nov. 2017, doi: 10.1056/nejmoa1702752.

[74] S. Russell *et al.*, "Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial," *The Lancet*, vol. 390, no. 10097, pp. 849–860, Aug. 2017, doi: 10.1016/S0140-6736(17)31868-8.

[75] J. R. Mendell *et al.*, "Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy," *New England Journal of Medicine*, vol. 377, no. 18, pp. 1713–1722, Nov. 2017, doi: 10.1056/nejmoa1706198.

[76] J. Corrigan-Curay, L. Sacks, and J. Woodcock, "Real-world evidence and real-world data for evaluating drug safety and effectiveness," Sep. 04, 2018, *American Medical Association*. doi: 10.1001/jama.2018.10136.

[77] P. Suwinski, C. K. Ong, M. H. T. Ling, Y. M. Poh, A. M. Khan, and H. S. Ong, "Advancing personalized medicine through the application of whole exome sequencing and big data analytics," 2019, *Frontiers Media S.A.* doi: 10.3389/fgene.2019.00049.

[78] M. C. Cornel, H. C. Howard, D. Lim, V. L. Bonham, and K. Wartiovaara, "Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?," *European Journal of Human Genetics*, vol. 27, no. 3, pp. 484–487, Mar. 2019, doi: 10.1038/s41431-018-0309-x.

[79] M. J. Khoury *et al.*, "A decade of public health genomics in the united states: Centers for disease control and prevention 1997-2007," Sep. 2008. doi: 10.1159/000153427.

[80] P. A. Hines, R. H. Guy, A. Brand, A. J. Humphreys, and M. Papaluca-Amati, "Regulatory Science and Innovation Programme for Europe (ReScIPE): A proposed model," *Br J Clin Pharmacol*, vol. 86, no. 12, pp. 2530–2534, Dec. 2020, doi: 10.1111/bcp.14099.